Next Article in Journal
Prevalence of Allergen-Specific IgE Positivity and Serum Immunoglobulin E Concentrations of Allergens in Dogs with Suspected Allergic Dermatitis Using the Multiple Allergen Simultaneous Test in South Korea
Previous Article in Journal
Proliferation in Minimal Invasive Samples of Canine Lymphomas: Ki67 Index in Previously Stained Cytology and Paired Cell Blocks
Previous Article in Special Issue
Integrated Study of Canine Mammary Tumors Histopathology, Immunohistochemistry, and Cytogenetic Findings
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Study of Oxidant/Antioxidant Profile in Dogs with Mammary Cancer Undergoing Mastectomy, During the Peri-Operative Period †

by
Angelos-Lauris Thomas
1,*,
Maria Karayannopoulou
1,
Tilemachos Anagnostou
1,
Dimitra Psalla
2,
Konstantinos Ioannou
1,
Argyrios Ginoudis
3,
Ioannis Savvas
1 and
Dimitra Pardali
3
1
Department of Clinical Studies-Companion Animal Clinic, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 11 St. Voutyra Street, 546 27 Thessaloniki, Greece
2
Laboratory of Pathology, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, University Campus, 541 24 Thessaloniki, Greece
3
Department of Clinical Studies-Diagnostic Laboratory, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 11 St. Voutyra Street, 546 27 Thessaloniki, Greece
*
Author to whom correspondence should be addressed.
Authors confirm that neither this manuscript nor any parts of its content are currently under consideration for publication with or published in another journal. However, some results of the submitted study were presented as a poster in the 29th FECAVA Eurocongress & 12th Hellenic Companion Animal Veterinary Congress—HVMS in Athens, Greece, 12–14 September 2024, and an abstract has been included in their online Abstract Book.
Vet. Sci. 2025, 12(6), 562; https://doi.org/10.3390/vetsci12060562
Submission received: 25 April 2025 / Revised: 30 May 2025 / Accepted: 5 June 2025 / Published: 8 June 2025
(This article belongs to the Special Issue New Insights into Canine Tumors)

Simple Summary

In cancer cases, any imbalance between Reactive Oxygen Species (ROS) production and host antioxidant capacity (oxidative stress), during the immediate post-operative period, is involved in cancer cell dissemination (micro-metastases); surgical trauma is considered the main cause for ROS production. Our objective was to investigate the blood oxidant/antioxidant profile in bitches with mammary cancer, hypothesizing that oxidative stress would be increased after mastectomy. In twelve bitches with mammary cancer, serum oxidant/antioxidant profile was evaluated chromatometrically using the d-ROMs (Reactive Oxygen Metabolite-derived compounds) and the BAP (biological antioxidant potential) tests, on the 1st day (before/after surgery), and on the 2nd, 3rd and 10th days post-operatively. Statistically significant differences (increases) were found in d-ROMS on the second and third post-operative day compared to the first day (before surgery) of measurement (p = 0.007 and p = 0.002, respectively). Our findings indicate a post-surgical oxidative stress increase potentially affecting patient outcome.

Abstract

In cancer cases, any imbalance between Reactive Oxygen Species (ROS) production and host antioxidant capacity (oxidative stress), during the immediate post-operative period, is involved in cancer cell dissemination (micro-metastases). Surgical trauma is considered the main cause for ROS production during that period. Increased oxidative stress has been found in dogs with mammary neoplasms. Our objective was to investigate the blood oxidant/antioxidant profile in bitches with mammary cancer, during the peri-operative period, hypothesizing that oxidative stress would be further increased after mastectomy. Twelve bitches with mammary cancer and no distant metastases, with a comparable extent of surgical wound and receiving the same anesthetic protocol, were included. Their serum oxidant/antioxidant profile was evaluated chromatometrically using the d-ROMs (Reactive Oxygen Metabolite-derived compounds) and the BAP (biological antioxidant potential) tests, on the 1st day (before/after surgery), and on the 2nd, 3rd and 10th days post-operatively. The ratio of d-ROMs and BAP values (oxidative stress index; OSI) was also calculated. Statistically significant differences (increases) were found only in d-ROMS on the second and third post-operative day compared to the first day (before surgery) of measurement (p = 0.007 and p = 0.002, respectively). Our findings indicate a post-surgical overproduction of ROS and therefore an oxidative stress increase potentially affecting patient outcome.

1. Introduction

Mastectomy is the only or the main treatment in most canine mammary cancer cases. However, it is well known from human and animal studies that surgery itself, as well as some drugs used in anesthesia/analgesia, induce immunosuppression during the immediate post-operative period potentially allowing residual cancer cells to proliferate and metastasize [1,2,3,4,5,6,7,8]. It has been reported that Reactive Oxygen Species (ROS) regulate many of the pathways which facilitate a number of cellular processes (adhesion, invasion, angiogenesis and proliferation) that are necessary for the successful dissemination of cancer cells during that period [9,10,11,12]. Surgical trauma is considered the main cause for ROS production [9,10,11,13]. Moreover, some drugs used in anesthesia for mastectomy can also induce ROS production [14,15].
Antioxidants from endogenous or exogenous origin act as a protective mechanism against the accumulation of ROS and the damage that they may induce, and contribute to the host immune defense. Any imbalance between ROS production and host antioxidant capacity that leads to the accumulation of ROS is defined as oxidative stress and is implicated in tumor growth and progression of the disease [10,11,13,16,17,18].
Tumor cells produce elevated levels of ROS compared to normal cells [11,19,20]. It has also been reported that in cancer cell lines, an inefficiency of the intracellular antioxidant system was found due to mutations of antioxidant enzymes, facilitating elevated ROS production by cancer cells [10]. Increased oxidative stress has been reported in dogs with mammary neoplasms compared to healthy controls [21,22,23,24], as in women with breast cancer [17,19,25,26,27,28,29]. Consequently, the use of antioxidants, not only for cancer prevention but also in cancer treatment, has been evaluated in many studies [18,20,21,28,30,31].
The aim of this study was to investigate the oxidant/antioxidant status in the blood of dogs with mammary cancer subjected to mastectomy, during the peri-operative period. We hypothesized that the existing oxidative stress in canine mammary cancer cases would be further increased after mastectomy due to surgical trauma and anesthesia potentially facilitating tumor metastases.

2. Materials and Methods

2.1. Animals

The animals included in the present study were selected from bitches with mammary tumors admitted to the University Companion Animal Clinic for diagnosis and therapeutic management (mastectomy). Inclusion criteria were as follows: histologically diagnosed malignant tumor(s) evaluated post-surgically, absence of distant metastases (clinical stage I, II or III of the disease according to the World Health Organization clinical staging system TNM) [32], comparable extent of surgical wound in all animals, and use of the same anesthetic protocol for mastectomy. Exclusion criteria included any other concurrent disease or treatment (at least six months before surgery) that is known to induce immunosuppression or increase oxidative stress. The type of surgery performed for tumor(s) excision was unilateral total mastectomy or bilateral regional mastectomy depending on the number of tumors and mammary glands involved [33]. In order to compare surgical wounds between dogs of different body size and weight, we used the term “extent of surgical wound”. It was defined as the % ratio of the wound surface area in m2/the body surface area (BSA) in m2, where wound surface area = maximum wound length × maximum wound width and BSA = K × W2/3 × 10−4 (K: 10.1 for dogs; W: body weight in grams) [34]. An initial number of 16 bitches with mammary tumors were subjected to mastectomy and blood sampling; however, four bitches were excluded after the post-surgical histological diagnosis of benign tumors. Therefore, a total of twelve bitches with mammary cancer were finally included in this study.
The study protocol was approved by our University Research Committee according to international guidelines on animal ethics and welfare (Date: 28 September 2022/No: 244751/2022). In addition, the owner’s consent was obtained for each dog that participated in the study.

2.2. Anesthetic Protocol

In this study, the anesthetic protocol for mastectomy was a protocol commonly used in veterinary practice. More specifically, pre-anesthetic medication included acepromazine (Acepromazine; Alfasan, The Netherlands) 0.05 mg kg−1 given intramuscularly (IM), morphine (morphine sulfate; Famar SA, Thiva, Greece) 0.2 mg kg−1 IM and meloxicam (Metacam; Boehringer Ingelheim Vetmedica GmbH, Ingelheim, Germany) 0.1 mg kg−1 subcutaneously (SC). Lactated Ringer’s solution (L-R Lactated Ringer’s Injection; Vioser, Trikala, Greece) was administered intravenously (IV) via the cephalic vein at a rate of 5 mL kg−1 h−1 until the end of surgery and anesthesia. Moreover, cefazolin (Vifazolin; Vianex, Kifisia, Greece) 20 mg kg−1 was given IV as prophylactic antibiotic treatment. Induction of anesthesia was carried out with propofol (Propofol MCT/LCT Fresenius; Fresenius KabiHellas, Marousi, Greece) IV, at an initial dose of 2 mg kg−1 and additional doses of 1 mg kg−1 as needed, whereas maintenance was performed with administration of isoflurane (AErrane; Baxter Healthcare Ltd., Norfolk, UK) in 100% oxygen through an appropriate cuffed endotracheal tube that was connected to the appropriate breathing system of an anesthetic machine. For intra-operative analgesia, fentanyl (Fentanyl; Janssen Pharmaceutica NV, Beerse, Belgium) was given IV at 0.1 μg kg−1 min−1 via a constant rate infusion until the end of surgery. For post-operative pain relief, morphine 0.1 mg kg−1 was given IM every 4 h for one day and meloxicam 0.1 mg kg−1 SC or per os every 24 h for five days. Additional rescue analgesia (morphine) was administered if indicated by pain assessments (Short Form of the Glasgow Composite Measure Pain Scale) performed every 2 h for the first 48 h postoperatively. The duration of surgery and the duration of anesthesia were recorded in all animals.

2.3. Histological Evaluation

Representative specimens obtained from the excised tumor(s) and lymph nodes were routinely processed and stained with hematoxylin and eosin for histological examination. The tumors were classified according to the Misdorp and colleagues [35] validated system.

2.4. Blood Measurements

On the day of mastectomy (1st day) and after a 12 h over-night fasting, before the administration of pre-anesthetic medication and at the end of surgery (1st day/pre and 1st day/post), as well as on the 2nd, 3rd and 10th post-operative day, 6 mL of blood was collected from each animal via jugular venipuncture. One mL of that blood was collected in EDTA-containing tubes for measurement of absolute numbers of white blood cells (WBCs) and neutrophils (NEUT) in an automated hematology analyzer (ADVIA 120; Siemens, Germany). The remaining 5 mL of blood was collected in tubes without any anti-coagulant for obtaining serum. The serum was then stored at −80 °C until measurements for evaluation of the oxidant/antioxidant profile of each dog were performed.
The oxidant/antioxidant status of each dog, during the peri-operative period, was evaluated chromatometrically in a spectrophotometric analyzer (Free Carpe Diem, Diacron Labs S.r.I., Grosseto, Italy) by using the d-ROMs (Reactive Oxygen Metabolite-derived compounds) test and the BAP (biological antioxidant potential) test. The d-ROMs test (Diacron Labs S.r.I., Grosseto, Italy) is a sensitive and well-established test for measuring the oxidation generated by free radicals in a sample of blood serum (fresh/frozen) or plasma and is expressed in Carratelli units (1 CARR U = 0.08 mg hydrogen peroxide/dL) [36,37,38,39]. The BAP test (Diacron Labs S.r.I., Grosseto, Italy) carried out in fresh/frozen serum or plasma and expressed in μmol/L provides a quantitative evaluation of the host biological antioxidant potential attributable to substances of endogenous or exogenous origin (e.g., albumin, uric acid, bilirubin, glutathione, ascorbic acid, tocopherols, etc.) [37,39,40,41]. Another value that was calculated was the oxidative stress index (OSI), which is the ratio of d-ROMs and BAP values and is expressed in Arbitrary Units (AU). For OSI calculations, the BAP values had to be converted from μmol/L to mmol/L [39,42].
Before every run of d-ROMs and BAP measurements, two-level (high and low) control material provided by the manufacturer was used, as well as calibrator material in case the control was out of range. In order to assess assay repeatability, the coefficient of variation (CV) of the d-ROMs and BAP tests was calculated by measuring in triplicate each sample of the first three dogs included in the study.

2.5. Statistical Analysis

Apriori power calculation concerning d-ROMs values revealed that 12 dogs were enough for a power >80% to detect statistically significant differences. The Kolmogorov–Smirnov test was used for assessing the normality of data distribution. A General Linear Model for repeated measures was used for comparisons between measurement times for d-ROMs, as well as for WBCs and NEUT measurements. Regarding BAP measurements and OSI values, a nonparametric test (Related-Samples Friedman’s Two-Way Analysis of Variance by Ranks) was used. For all statistical analyses, commercially available software (SPSS version 19.0; IBM-SPSS Science, Chicago, IL, USA) was utilized and data were expressed as mean ± standard deviation (SD). Significant differences were declared at p ≤ 0.05.

3. Results

3.1. Animals: Clinical and Histological Characteristics of Mammary Tumors

Most of the bitches included in this study were mongrels (8/12). The animals were aged 8–14 years (mean ± SD: 10.67 ± 1.97) with a weight range from 7 to 28 Kg. Only five bitches were intact, whereas the remaining seven had undergone ovariohysterectomy 2–4 years before mastectomy, due to pyometra. According to TNM classification, four of the included animals had mammary cancer of clinical stage I, four of stage II and four of stage III. Unilateral total mastectomy was performed in nine cases and bilateral regional mastectomy in three cases. Histological examination revealed that 10 bitches had carcinomas, one had multiple malignant mixed tumors and one had a sarcoma tumor. Lymph node metastasis was found only in one carcinoma case.
The “extent of surgical wound” ranged from 4.20 to 6.57% (mean ± SD: 5.31 ± 0.8%) of BSA showing a comparable extent of surgical wound in all cases.
The duration of surgery was from 60 to 240 min (mean ± SD: 123.33 ± 53.5 min), and the duration of anesthesia was from 110 to 270 min (mean ± SD: 200.83 ± 58.2 min).

3.2. Blood Measurements

The mean absolute numbers of WBCs and NEUT at each measurement time are presented in Figure 1. There was a statistically significant increase (p = 0.000) in both variables on the second and third post-operative day compared to both first day values (pre- and post-surgery). A peak of these increases was observed on day 2. On the 10th post-operative day, the mean absolute number of WBCs, although this decreased significantly compared to day 3 (p = 0.011), was still significantly higher than the 1st day/pre (p = 0.002) and 1st day/post (p = 0.005) values. Similarly, on the same day (10th), the mean absolute number of NEUT was found to be decreased (p = 0.006) compared to day 3, but it was higher than the first day values (first day/pre: p = 0.006 and first day/post: p = 0.014).
The CV for d-ROMs and BAP tests was 3.2% and 5.1%, respectively. The results of d-ROMs measurements are presented in Table 1. Statistically significant differences (increased values) were found in d-ROMs on the second and third post-operative day compared to the first day/pre measurement (p = 0.007 and p = 0.002, respectively), as well as between the third post-operative day and the first day/post measurements (p = 0.03). On the 10th day, the mean d-ROMs value was still higher than both the first day values, but no significant differences were found.
All the BAP post-operative changes (Table 2) were not statistically significant compared to the first day/pre measurement. More specifically, the mean BAP value was increased immediately after mastectomy (first day/post) but decreased on the second post-operative day (when there was a significant increase in d-ROMs). Subsequently, the mean BAP value was increased again on the 3rd post-operative day (when d-ROMs mean value was further significantly increased) and on the 10th day (when d-ROMs value was lower than that on day 3).
Regarding the mean OSI value (Table 3), although it was elevated immediately after mastectomy and on the second or even the third post-operative day, no statistically significant differences between measurement times were found.

4. Discussion

Surgical trauma is considered the main cause for ROS production during the immediate post-operative period [10,11]. More specifically, due to surgical trauma and during the acute inflammatory phase of wound healing, large amounts of inflammatory cells such as neutrophils and macrophages are recruited at the site of surgical injury. These cells are known to induce ROS production not only through phagocytic activity, but also through the release of proinflammatory soluble mediators such as cytokines, chemokines and growth factors. In cancer cases, these soluble mediators activate a family of enzymes in cancer cells, the so-called Nox [nikotinamide adenine dinucleotide phosphate (NADPH) oxidase] enzymes that produce ROS [9,10,11,13]. As known, ROS facilitate cellular processes that are necessary for the dissemination of remaining tumor cells post-operatively [9,10,11,13,17,23,43]. In our study, increased numbers of WBCs and NEUT were found in blood, on the second and third post-mastectomy day (Figure 1), when there was also a significant increase in d-ROMs (Table 1). Similarly, in two recent studies [7,8] on the effect of anesthesia and surgery on host immunity in dogs with mammary cancer undergoing mastectomy, significantly increased numbers of WBCs and NEUT were found on day 3 post-surgery, when suppression in cell-mediated immunity and particularly T-lymphocytes (CD3+) and some of their subpopulations was also detected. It has been reported that in cancer cases, surgery-induced immunosuppression usually reaches a peak about day 3 post-surgery and lasts for about 10 days [3,5,7,8]. Therefore, although inflammatory cells are essential for surgical wound healing, they could also be involved in cancer progression, in the immediate post-operative period [6].
Oxidative stress plays an important role in breast cancer development and progression in both humans and dogs, as revealed from studies where increased levels of oxidation products and reduced antioxidants were found in the blood of cancer patients compared to healthy controls [17,24,26,27,42]. However, in a few other studies, various contradictory results have been reported [23,29,44].
Since many factors contribute to oxidative stress induction and a variety of antioxidants of endogenous (enzymatic and non-enzymatic) and exogenous origin are implicated [16,17], relevant studies have evaluated many different biomarkers of oxidant and particularly antioxidant status [17,18,23,26,29]. In the present study, the d-ROMs and BAP tests used for evaluating blood oxidant/antioxidant profile are considered to be two simple but accurate, reliable and suitable tools for clinical oxidative status evaluation in dogs [37,40]. Pasquini and colleagues [37], by using the same tests in a population of 130 healthy Labrador dogs aged 1–5 years, were the first that reported reference values for d-ROMs and BAP, which were from 54.4 to 91.4 CARR U and from 1440 to 3260 μmol/L, respectively.
In this study, the level of d-ROMs, which was pre-surgically in the upper limit of normal range according to the previously mentioned reference values [37], was significantly increased on the 2nd and 3rd post-operative day, but not on the 10th day (Table 1). Regarding the antioxidant profile, the mean BAP value changes after mastectomy (Table 2), although not statistically significant and always below the lower limit of normal range, might reflect efforts of the body to resist against the increased ROS production. Our findings, therefore, may reflect an inefficiency of host antioxidant defense system to compensate for the accumulation of ROS after mastectomy.
In a human study [26], in 35 breast cancer patients that were subjected to modified radical mastectomy, the pre-surgically elevated (compared to healthy controls) serum levels of the oxidative stress biomarker malondialdehyde (MDA) were found to be significantly decreased two weeks after surgery. In the same study, any changes found in serum levels of total antioxidant capacity (TAC) were not significant, as in our study. In a large number of dogs with malignant mammary tumors that were subjected to total (unilateral/bilateral) or regional mastectomy, a significant reduction in serum MDA levels was found 30 days after surgery compared to prior therapy values [24]. In dogs with mammary gland tumors subjected to mastectomy and ovariohysterectomy, the serum concentration of thiobarbituric acid reactive substances (TBARS), a marker of oxidative status, was found to be higher 10 min after surgery compared to 10 days after surgery [21]. In a study performed in human breast cancer patients, the high plasma total oxidant status (TOS) and OSI values and the low total antioxidant status (TAS) value compared to healthy controls (assessed 24 h before surgery) were found unchanged in the first post-operative month [42]. Generally, it would be expected that, in the early post-operative period, biomarkers of oxidant status would be found to be increased due to surgery and antioxidant ones being decreased, while in later periods, the opposite should be the case. However, according to the literature, as in the aforementioned studies, this is not always the case.
In experimental and clinical studies, it has been reported that some anesthetic or analgesic drugs can influence inflammation, immune responses, cancer cell proliferation and metastasis [3,43]. The results of studies on volatile anesthetics and opioids, such as isoflurane and morphine/fentanyl used in our study, are controversial [3,15]. It has been reported that isoflurane induced oxidative stress in human patients undergoing major surgeries, but it was considered safe in cases of minor surgeries [15]. On the other hand, propofol (used for induction of anesthesia in the present study) has shown anti-inflammatory and antioxidant properties, probably due to chemical similarity with other known antioxidants such as a-tocopherol [12,14,43]. In cancer surgery, therefore, the use of anesthetic drugs with antioxidant properties would be advisable. In the present study, it was decided to use an anesthetic/analgesic protocol that is commonly used in veterinary practice, although it included drugs that might increase oxidative stress. This decision was made in order to better reflect the situation in current veterinary clinical practice.
Although antioxidants play an important role in reducing oxidative stress, their role in preventing tumor growth and metastasis and the benefit of antioxidant supplementation in cancer treatment is controversial. Supplementation above physiological doses and taken for a long period of time could increase the risk of cancer or the survival/growth of cancer cells, and may be harmful in cancer chemotherapy and radiotherapy [11,18,20,21,28,30,31]. Nevertheless, the contribution of logical supplementation of antioxidant vitamins or other natural/synthetic antioxidant compounds to cancer prevention and treatment cannot be ignored [18,20].
Concerning the limitations of the present study, the wide weight range (7–28 Kg) and consequently the differences in body and wound size of the included animals could be considered as a limitation. However, the “extent of surgical wound”, a parameter calculated according to the body surface area, was considered as a safe inclusion criterion instead of wound size. Furthermore, our results on blood oxidant/antioxidant status could not have been influenced by parameters such as animal’s age or tumor type, since they were revealed from measurements over time (before and after surgery). However, the relatively small number of animals included in this study may have limited the possibility to detect any statistically significant differences in BAP, and subsequently, in OSI values between measurement times.

5. Conclusions

In bitches with mammary cancer, the significantly increased levels of d-ROMs on the second and third post-operative day may reflect an inability of the body to avoid the post-mastectomy accumulation of ROS and an oxidative stress increase. Further studies are needed to conclude whether interventions (e.g., use of anesthetic drugs with antioxidant properties or use of selective antioxidants for a short period peri-operatively) could be proved advisable for eliminating the post-surgical increase in oxidative stress, which might facilitate tumor cell dissemination and affect the patient’s outcome.

Author Contributions

Conceptualization: M.K. and A.-L.T.; methodology: M.K. and A.-L.T.; formal analysis: I.S.; investigation: A.-L.T., M.K., T.A. and D.P. (Dimitra Psalla), K.I., A.G. and D.P. (Dimitra Pardali); resources: K.I.; data curation: M.K.; writing—original draft preparation: M.K. and A.-L.T.; writing—reviewing and editing: T.A. and D.P. (Dimitra Pardali); visualization: A.-L.T. and M.K.; supervision: M.K.; project administration: A.-L.T.; funding acquisition: A.-L.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Research Committee of Aristotle University of Thessaloniki, Greece, under Grant number: 75060.

Institutional Review Board Statement

The study protocol was approved, according to international guidelines on animal ethics and welfare, by the Research Committee of Aristotle University of Thessaloniki, Greece (Date: 28 September 2022/No: 244751/2022).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The raw data supporting the conclusion of this article will be made available by the authors on request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Hogan, B.V.; Peter, M.B.; Shenoy, H.G.; Horgan, K.; Hughes, T.A. Surgery induced immunosuppression. Surgeon 2011, 9, 38–43. [Google Scholar] [CrossRef] [PubMed]
  2. Alieva, M.; van Rheenen, J.; Broekman, M.L.D. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. Clin. Exp. Metastasis 2018, 35, 319–331. [Google Scholar] [CrossRef]
  3. Kim, R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. J. Transl. Med. 2018, 16, 8. [Google Scholar] [CrossRef]
  4. Perry, J.A.; Douglas, H. Immunomodulatory effects of surgery, pain, and opioids in cancer patients. Vet. Clin. Small Anim. 2019, 49, 981–991. [Google Scholar] [CrossRef]
  5. Onuma, A.E.; Zhang, H.; Gil, L.; Huang, H.; Tsung, A. Surgical stress promotes tumor progression: A focus on the impact of the immune response. J. Clin. Med. 2020, 9, 4096. [Google Scholar] [CrossRef]
  6. Tang, F.; Tie, Y.; Tu, C.; Wei, X. Surgical trauma-induced immunosuppression in cancer: Resent advances and the potential therapies. Clin. Transl. Med. 2020, 10, 199–223. [Google Scholar] [CrossRef]
  7. Karayannopoulou, M.; Anagnostou, T.; Margariti, A.; Kritsepi-Konstantinou, M.; Psalla, D.; Savva, I.; Kazakos, G. Effect of anaesthesia for mastectomy on cell-mediated immunity in dogs with mammary cancer. Vet. Anaesth. Analg. 2022, 49, 265–274. [Google Scholar] [CrossRef]
  8. Karayannopoulou, M.; Anagnostou, T.; Margariti, A.; Kritsepi-Konstantinou, M.; Psalla, D.; Thomas, A.-L.; Savvas, I. Effect of major versus minor mastectomy on host immunity in canine mammary cancer. Vet. Immunol. Immunopathol. 2022, 246, 110403. [Google Scholar] [CrossRef]
  9. Brown, N.S.; Bicknell, R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: Its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3, 323–327. [Google Scholar] [CrossRef]
  10. O’Leary, D.P.; Wang, J.H.; Cotter, T.G.; Redmond, H.P. Less stress, more success? Oncological implications of surgery-induced oxidative stress. Gut 2013, 62, 461–470. [Google Scholar] [CrossRef]
  11. Moloney, J.N.; Cotter, T.G. ROS signaling in the biology of cancer. Semin. Cell Dev. Biol. 2018, 80, 50–64. [Google Scholar] [CrossRef] [PubMed]
  12. Irwin, M.G.; Chung, C.K.E.; Ip, K.Y.; Wiles, M.D. Influence of propofol-based total intravenous anaesthesia on peri-operative outcome measures: A narrative review. Anaesthesia 2020, 75, e90–e100. [Google Scholar] [CrossRef] [PubMed]
  13. Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Oxidative stress, inflammation and cancer: How are they linked? Free Radic. Biol. Med. 2010, 49, 1603–1616. [Google Scholar] [CrossRef]
  14. Lee, J.Y. Oxidative stress due to anesthesia and surgical trauma and comparison of the effects of propofol and thiopental in dogs. J. Vet. Med. Sci. 2012, 74, 663–665. [Google Scholar] [CrossRef]
  15. Lee, Y.-M.; Song, B.C.; Yeum, K.-J. Impact of volatile anesthetics on oxidative stress and inflammation. Biomed. Res. Int. 2015, 2015, 242709. [Google Scholar] [CrossRef]
  16. Lee, J.D.; Cai, Q.; Ou Shu, X.; Nechuta, S.J. The role of biomarkers of oxidative stress in breast cancer risk and prognosis: A systematic review of the epidemiologic literature. J. Women’s Health 2017, 26, 467–482. [Google Scholar] [CrossRef]
  17. Jelik, M.D.; Mandic, A.D.; Maricic, S.M.; Srdjenovic, B.U. Oxidative stress and its role in cancer. J. Can. Res. Ther. 2021, 17, 22–28. [Google Scholar] [CrossRef]
  18. Zahra, K.F.; Lefter, R.; Ali, A.; Abdellah, E.-C.; Trus, K.; Ciobica, A.; Timofte, D. The involvement of the oxidative stress status in cancer pathology: A double view on the role of the antioxidants. Oxid. Med. Cell Longev. 2021, 2021, 9965916. [Google Scholar] [CrossRef]
  19. Calaf, G.M.; Urzua, U.; Termini, L.; Aguayo, F. Oxidative stress in female cancers. Oncotarget 2018, 9, 23824–23842. [Google Scholar] [CrossRef]
  20. Marioli-Sapsakou, G.-K.; Kourti, M. Targeting production of reactive oxygen species as an anticancer strategy. Anticancer Res. 2021, 41, 5881–5902. [Google Scholar] [CrossRef]
  21. Stavinohová, R.; Lorenzová, J.; Papežiková, I.; Borkovcová, I.; Pfeifr, J.; Lojek, A.; Mrázová, M.; Crha, M. Markers of oxidative and antioxidative activity in female dogs with mammary gland tumour with and without additional vitamin E supplementation. Acta Vet. Brno 2012, 81, 275–280. [Google Scholar] [CrossRef]
  22. Macotpet, A.; Suksawat, F.; Sukon, P.; Pimpakdee, K.; Pattarapanwichien, E.; Tangrassameeprasert, R.; Boonsiri, P. Oxidative stress in cancer-bearing dogs assessed by measuring serum malondialdehyde. BMC Vet. Res. 2013, 9, 101. [Google Scholar] [CrossRef]
  23. Machado, V.S.; Crivellenti, L.Z.; Bottari, N.B.; Tonin, A.A.; Pelinson, L.P.; Borin-Crivellenti, S.; Santana, A.E.; Torbitz, V.D.; Moresco, R.N.; Duarte, T.; et al. Oxidative stress and inflammatory response biomarkers in dogs with mammary carcinoma. Pathol.-Res. Pract. 2015, 211, 677–681. [Google Scholar] [CrossRef]
  24. Russo, C.; Simonelli, S.M.; Luz, M.B.; Carrera, A.C.; Moreno, I.F.; Bracarense, A.P.F.R.L. Oxidative stress in female dogs with mammary neoplasms. Pesq. Vet. Bras. 2021, 41, e06742. [Google Scholar] [CrossRef]
  25. Bhattacharjee, J.; Jongdand, S.; Shind, R.K.; Goswami, S. Assessment of oxidative stress in breast cancer patients: A hospital based study. Int. J. Basic Clin. Pharmacol. (IJBCP) 2018, 7, 966–970. [Google Scholar] [CrossRef]
  26. Hewala, T.I.; Abo Elsoud, M.R. The clinical significance of serum oxidative stress biomarkers in breast cancer females. Med. Res. J. 2019, 4, 1–7. [Google Scholar]
  27. Hoseini, H.; Saravi, M.K.; Shahraki, S.; Sarani, A.; Sarabandi, A. Evaluation of oxidative stress biomarkers in patients with breast cancer compared with healthy subjects. J. Chem. Health Risks (JCHR) 2021, 11, 13–17. [Google Scholar]
  28. Pantelimon, I.; Gales, L.N.; Zgura, A.; Serbanescu, G.L.; Georgescu, D.E.; Nita, I.; Manolescu, L.S.C.; Stancu, A.M.; Gruia, M.I.; Anghel, R.M.; et al. Analysis of oxidative stress in patients with breast cancer and obesity. Ann. Med. Health Sci. Res. 2021, 11, 1578–1585. [Google Scholar]
  29. Danesh, H.; Ziamajidi, N.; Mesbah-Namin, S.A.; Nafisi, N.; Abbasalipourkabir, R. Association between oxidative stress parameters and hematological indices in breast cancer patients. Int. J. Breast Cancer 2022, 2022, 1459410. [Google Scholar] [CrossRef]
  30. Freeman, L.M. Antioxidants in cancer treatment: Helpful or harmful? Compend. Contin. Educ. Vet. 2009, 31, 154–158. [Google Scholar]
  31. Morry, J.; Ngamcherdtrakul, W.; Yantasee, W. Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles. Redox Biol. 2017, 11, 240–253. [Google Scholar] [CrossRef] [PubMed]
  32. Owen, L.N. The TNM Classification of Tumors in Domestic Animals, 1st ed.; World Health Organization: Geneva, Switzerland, 1980; pp. 20–80. [Google Scholar]
  33. Papazoglou, L.G.; Basdani, E.; Rabidi, S.; Patsikas, M.N.; Karayannopoulou, M. Current surgical options for mammary tumor removal in dogs. J. Veter. Sci. Med. 2014, 2, 6. [Google Scholar] [CrossRef]
  34. Saganuwan, S.A. Derivation of a unique body surface area (bsa) formula for calculation of relatively safe doses of dog and human anticancer drugs. J. Cancer Sci. Ther. 2017, 9, 690–704. [Google Scholar] [CrossRef]
  35. Misdorp, W.; Else, R.W.; Hellmén, E.; Lipscomb, T.P. Histological Classification of Mammary Tumours of the Dog and the Cat, Vol. VII; Armed Forces Institute of Pathology and American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology: Washington, DC, USA, 1999; pp. 11–29. [Google Scholar]
  36. Alberti, A.; Bolognini, L.; Macciantelli, D.; Caratelli, M. The radical cation of N,N-diethyl-para-phenylendiamine: A possible indicator of oxidative stress in biological samples. Res. Chem. Intermed. 2000, 26, 253–267. [Google Scholar] [CrossRef]
  37. Pasquini, A.; Luchetti, E.; Marchetti, V.; Cardini, G.; Iorio, E.L. Analytical performances of d-ROMs test and BAP test in canine plasma. Definition of the normal range in healthy Labrador dogs. Vet. Res. Commun. 2008, 32, 137–143. [Google Scholar] [CrossRef]
  38. Jansen, E.; Ruskovska, T. Serum biomarkers of (anti)oxidant status for epidemiological studies. Int. J. Mol. Sci. 2015, 16, 27378–27390. [Google Scholar] [CrossRef]
  39. Oikonomodis, I.L. Study of the Changes in Haematological, Biochemical and Hormonal Parameters, as Well as the Redox Status of the Blood of Rams During Reproductive Activity. Ph.D. Thesis, Aristotle University of Thessaloniki (A.U.Th.), Thessaloniki, Greece, 2017. [Google Scholar]
  40. Finotello, R.; Pasquini, A.; Meucci, V.; Lippi, I.; Rota, A.; Guidi, G.; Marchetti, V. Redox status evaluation in dogs affected by mast cell tumour. Vet. Comp. Oncol. 2012, 12, 120–129. [Google Scholar] [CrossRef]
  41. Jansen, E.H.J.M.; Beekhof, P.K.; Viezeliene, D.; Muzakova, V.; Skalicki, J. Long-term stability of oxidative stress biomarkers in human serum. Free Radic. Res. 2017, 51, 970–977. [Google Scholar] [CrossRef]
  42. Zengin, I.; Koçer, B.; Demiray, T.; Yilmaz, K. Prognostic value and significance of oxidative stress in breast cancer. Online Turk. J. Health Sci. (OTJHS) 2022, 7, 453–459. [Google Scholar] [CrossRef]
  43. Hiller, J.G.; Perry, N.J.; Poulogiannis, G.; Riedel, G.B.; Sloan, E.K. Perioperative events influence cancer recurrence risk after surgery. Nat. Rev. Clin. Oncol. 2018, 15, 205–218. [Google Scholar] [CrossRef]
  44. Enginler, S.O.; Toydemir, T.S.F.; Ates, A.; Ozturk, B.; Erdogan, O.; Ozdemir, S.; Kirsan, I.; Or, M.E.; Arun, S.S.; Barutsu, U.B. Examination of oxidative/antioxidative status and trace element levels in dogs with mammary tumors. Bulg. J. Agric. Sci. 2015, 21, 1086–1091. [Google Scholar]
Figure 1. Absolute numbers (mean values × 103/μL) of white blood cells (WBCs) and neutrophils (NEUT) in the blood of 12 bitches with mammary cancer undergoing mastectomy, measured prior to anesthesia (1st day/pre), at the end of surgery (1st day/post) and on 2nd, 3rd and 10th post-operative days. *: significant increase (p = 0.000) in WBCs and NEUT on 2nd and 3rd post-operative days compared to both 1st day values; †: significant decrease in WBCs (p = 0.011) and NEUT (p = 0.006) compared to 3rd post-operative day values; ‡: significant increase compared to 1st day values in WBCs (1st day/pre: p = 0.002 and 1st day/post: p = 0.005) and in NEUT (1st day/pre: p = 0.006 and 1st day/post: p = 0.014).
Figure 1. Absolute numbers (mean values × 103/μL) of white blood cells (WBCs) and neutrophils (NEUT) in the blood of 12 bitches with mammary cancer undergoing mastectomy, measured prior to anesthesia (1st day/pre), at the end of surgery (1st day/post) and on 2nd, 3rd and 10th post-operative days. *: significant increase (p = 0.000) in WBCs and NEUT on 2nd and 3rd post-operative days compared to both 1st day values; †: significant decrease in WBCs (p = 0.011) and NEUT (p = 0.006) compared to 3rd post-operative day values; ‡: significant increase compared to 1st day values in WBCs (1st day/pre: p = 0.002 and 1st day/post: p = 0.005) and in NEUT (1st day/pre: p = 0.006 and 1st day/post: p = 0.014).
Vetsci 12 00562 g001
Table 1. Measurements of d-ROMs (mean ± standard deviation) expressed in Carratelli Units (CARR U) in the blood serum of 12 bitches with mammary cancer undergoing mastectomy, on 1st day just before and after surgery (1st day/pre; 1st day/post) and on days 2nd, 3rd and 10th post-surgery.
Table 1. Measurements of d-ROMs (mean ± standard deviation) expressed in Carratelli Units (CARR U) in the blood serum of 12 bitches with mammary cancer undergoing mastectomy, on 1st day just before and after surgery (1st day/pre; 1st day/post) and on days 2nd, 3rd and 10th post-surgery.
Timed-ROMs (CARR U); Mean ± Standard Deviation
1st day/pre89.50 ± 18.9 a,b
1st day/post95.33 ± 23.6 c
2nd day105.08 ± 25.2 a
3rd day119.25 ± 20.3 b,c
10th day104.42 ± 25.4
Statistically significant differences between measurements, a: p = 0.007; b: p = 0.002); c: p = 0.03; d-ROMs: Reactive Oxygen Metabolite-derived compounds.
Table 2. Measurements of BAP (mean ± standard deviation) expressed in μmol/L in the blood serum of 12 bitches with mammary cancer undergoing mastectomy, on 1st day just before and after surgery (1st day/pre; 1st day/post) and on days 2nd, 3rd and 10th post-surgery.
Table 2. Measurements of BAP (mean ± standard deviation) expressed in μmol/L in the blood serum of 12 bitches with mammary cancer undergoing mastectomy, on 1st day just before and after surgery (1st day/pre; 1st day/post) and on days 2nd, 3rd and 10th post-surgery.
TimeBAP (μmol/L); Mean ± Standard Deviation
1st day/pre1218.82 ± 605.1
1st day/post1406.63 ± 725.9
2nd day1070.46 ± 577.2
3rd day1214.73 ± 631.7
10th day1299.12 ± 654.5
BAP: biological antioxidant potential.
Table 3. Oxidative stress index (OSI) values (mean ± standard deviation) expressed in Arbitrary Units (AU) in the blood serum of 12 bitches with mammary cancer undergoing mastectomy, on 1st day just before and after surgery (1st day/pre; 1st day/post) and on days 2nd, 3rd and 10th post-surgery.
Table 3. Oxidative stress index (OSI) values (mean ± standard deviation) expressed in Arbitrary Units (AU) in the blood serum of 12 bitches with mammary cancer undergoing mastectomy, on 1st day just before and after surgery (1st day/pre; 1st day/post) and on days 2nd, 3rd and 10th post-surgery.
TimeOSI Value (AU); Mean ± Standard Deviation
1st day/pre107.39 ± 94.8
1st day/post175.14 ± 355.6
2nd day198.18 ± 332.2
3rd day117.27 ± 49.7
10th day99.99 ± 57.3
OSI: the ratio of d-ROMs (in CARR U) and BAP (in mmol/L) values.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Thomas, A.-L.; Karayannopoulou, M.; Anagnostou, T.; Psalla, D.; Ioannou, K.; Ginoudis, A.; Savvas, I.; Pardali, D. Study of Oxidant/Antioxidant Profile in Dogs with Mammary Cancer Undergoing Mastectomy, During the Peri-Operative Period. Vet. Sci. 2025, 12, 562. https://doi.org/10.3390/vetsci12060562

AMA Style

Thomas A-L, Karayannopoulou M, Anagnostou T, Psalla D, Ioannou K, Ginoudis A, Savvas I, Pardali D. Study of Oxidant/Antioxidant Profile in Dogs with Mammary Cancer Undergoing Mastectomy, During the Peri-Operative Period. Veterinary Sciences. 2025; 12(6):562. https://doi.org/10.3390/vetsci12060562

Chicago/Turabian Style

Thomas, Angelos-Lauris, Maria Karayannopoulou, Tilemachos Anagnostou, Dimitra Psalla, Konstantinos Ioannou, Argyrios Ginoudis, Ioannis Savvas, and Dimitra Pardali. 2025. "Study of Oxidant/Antioxidant Profile in Dogs with Mammary Cancer Undergoing Mastectomy, During the Peri-Operative Period" Veterinary Sciences 12, no. 6: 562. https://doi.org/10.3390/vetsci12060562

APA Style

Thomas, A.-L., Karayannopoulou, M., Anagnostou, T., Psalla, D., Ioannou, K., Ginoudis, A., Savvas, I., & Pardali, D. (2025). Study of Oxidant/Antioxidant Profile in Dogs with Mammary Cancer Undergoing Mastectomy, During the Peri-Operative Period. Veterinary Sciences, 12(6), 562. https://doi.org/10.3390/vetsci12060562

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop